Vertex Pharmaceuticals Reports Strong Q1 2024 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported a 13% increase in product revenue in the first quarter of 2024, driven by strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets and label extensions. With net product revenue rising both in the U.S. and internationally, Vertex’s strategic moves, including the recent acquisition of Alpine Immune Sciences, are closely watched by investors and industry analysts.